论文部分内容阅读
目的探讨难治性心力衰竭(心衰)患者分别选择硝普钠以及冻干重组人脑利钠肽(新活素)治疗的临床效果。方法 82例难治性心衰患者作为实验对象,凭借数字奇偶法分为观察组与对照组,每组41例。对照组采用硝普钠治疗,观察组采用新活素治疗,比较两组患者治疗后心功能指标水平及临床疗效。结果观察组患者临床治疗总有效率为97.56%,明显高于对照组的70.73%,差异具有统计学意义(P<0.05)。对照组患者治疗后左室舒张末期内径(Lv EDd)为(62.82±7.39)mm、B型脑钠肽(BNP)为(174.91±42.85)pg/ml、左心室射血分数(LVEF)为(40.39±2.62)%,观察组患者治疗后LVEDd为(61.32±7.39)mm、BNP为(137.82±36.83)pg/ml、LVEF为(41.55±2.13)%;观察组患者治疗后LVEF及BNP水平均明显优于对照组,差异具有统计学意义(P<0.05);两组患者LVEDd比较差异无统计学意义(P>0.05)。结论临床在开展难治性心衰治疗工作期间,新活素药物的有效应用,有利于心功能指标的改善以及临床治疗效果的提高,从而优化难治性心衰患者的预后。
Objective To investigate the clinical effects of sodium nitroprusside and lyophilized recombinant human brain natriuretic peptide (NSAID) in patients with refractory heart failure (CHF). Methods 82 patients with refractory heart failure as experimental subjects, by virtue of digital parity method divided into observation group and control group, 41 cases in each group. The control group was treated with sodium nitroprusside. The observation group was treated with neomycin, and the cardiac function indexes and clinical effects were compared between the two groups after treatment. Results The total effective rate of clinical treatment in observation group was 97.56%, which was significantly higher than that in control group (70.73%), the difference was statistically significant (P <0.05). The Lv EDd was (62.82 ± 7.39) mm, the BNP was (174.91 ± 42.85) pg / ml, the left ventricular ejection fraction (LVEF) was 40.39 ± 2.62)%. After treatment, LVEDd was (61.32 ± 7.39) mm in BNP group and (137.82 ± 36.83) pg / ml in BNP group and (41.55 ± 2.13)% in LVEF group. The levels of LVEF and BNP in the observation group were The difference was statistically significant (P <0.05). There was no significant difference in LVEDd between the two groups (P> 0.05). Conclusions The clinical application of new active drugs during the treatment of refractory heart failure is beneficial to the improvement of cardiac function indexes and the improvement of clinical therapeutic effects so as to optimize the prognosis of patients with refractory heart failure.